

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE
COVERAGE INFORMATION AND SPECIAL CONSIDERATIONS**

General Immunization Billing Requirements:

Florida Medicaid providers administering vaccines to Florida Medicaid recipients enrolled in the fee-for-service delivery system must submit two Current Procedural Terminology (CPT) codes on the claim for reimbursement of administration from Florida Medicaid: (1)The vaccine product code AND (2)The vaccine administration code. A corresponding administration code must be submitted for each vaccine administered during the same visit on the claim form.

Vaccines for Children (VFC) Program Reimbursement Guidelines:

Florida Medicaid providers receiving vaccine products through the Vaccine for Children (VFC) Program for fee-for-service recipients 0 through 18 years of age are reimbursed for the administration of the vaccine(s) only. Vaccine product codes are reimbursed at \$0.00. Vaccine administration codes are reimbursed in accordance with rates established on this fee schedule.

MediKids Guidelines:

MediKids enrolls children one through four years of age. MediKids enrollees are eligible for all immunizations recommended by the Advisory Committee on Immunization Practices (ACIP) for this age group. However, MediKids enrollees are not eligible to receive products provided through the VFC Program. Florida Medicaid providers who administer vaccines to MediKids enrollees are to be reimbursed for the vaccine products and administration services by the enrollee's Managed Care Plan.

Mid-level Practitioner Reimbursement:

Administration services are reimbursed at 80% of the maximum fee when performed by an advanced practice registered nurse (APRN), physician's assistant (PA), or registered pharmacist (RPh). Vaccine product codes are reimbursed in accordance with rates established on this fee schedule.

COVID-19 Vaccine Billing and Reimbursement Guidelines:

Florida Medicaid providers administering COVID-19 vaccines to Florida Medicaid recipients enrolled in the fee-for-service delivery system must submit the CPT code for the specific vaccine product in conjunction with the COVID-19-specific vaccine administration code on the claim for reimbursement. The product CPT code and the COVID-19 administration code must be submitted for each vaccine dose administered on the claim form.

MPox Vaccine Billing and Reimbursement Guidelines:

Jynneos is eligible for the listed reimbursement rate for dates of service beginning on 08/01/2024.

***Influenza Vaccine Billing and Reimbursement Guidelines:**

CPT codes for quadrivalent formulations of the Influenza vaccine (2023 - 2024 Flu Season) are to be used for claims with dates of service through 04/30/2024. CPT codes for trivalent formulations of the Influenza vaccine (2024-2025 Flu Season) are eligible for claim reimbursement for dates of service beginning on 05/01/2024. Vaccine product codes are reimbursed in accordance with rates established on this fee schedule in conjunction with the billing and reimbursement guidelines stated here regarding date of service for submitted claims.

^ Respiratory Syncytial Virus monoclonal antibody codes have specific administration codes that must be billed together.

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2024

CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
GENERAL VACCINE ADMINISTRATION CODES					
90460		Administration of first vaccine or toxoid component through 18 years of age, with counseling		0-18	10.00
90471		Administration of one vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular)		0+	10.00
90472		Administration of each additional vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular)		0+	10.00
90473		Immunization administration by intranasal or oral route of one vaccine, single or combination vaccine/toxoid.		0+	10.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2024

CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
90474		Administration of each additional intranasal or oral vaccine (single or combination vaccine/toxoid)		0+	10.00
MPOX					
90611		Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use [<i>Jynneos</i>]	1	18+	270.00
HEPATITIS B					
90739		Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule for intramuscular use [<i>Heplisav-B</i>]	1	18	0.00
90739	HA	Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule for intramuscular use [<i>Heplisav-B</i>]	1	19+	140.60
90740		Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use [<i>Recombivax HB - Dialysis formulation</i>]	1	18+	158.15
90743		Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use [<i>Recombivax-B-ADULT</i> ; <i>Engerix-B-ADULT</i>]	1	11 - 15	0.00
90744		Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use [<i>Recombivax-PEDS</i> ; <i>Engerix-B-PEDS</i>]	1	0-18	0.00
90746		Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule for intramuscular use [<i>Recombivax-B-ADULT</i> ; <i>Engerix-B-ADULT</i>]	1	19+	68.16
90759		Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use [<i>PreHevbrio</i>]	1	18	0.00
90759	HA	Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use [<i>PreHevbrio</i>]	1	19+	65.50
ROTAVIRUS (RV)					
90680		Rotavirus vaccine, pentavalent [RV5], 3 dose schedule, live, for oral use [<i>RotaTeq</i>]	1	0-1	0.00
90681		Rotavirus vaccine, human, attenuated [RV1], 2 dose schedule, live, for oral use [<i>Rotarix</i>]	1	0-1	0.00
DIPHTHERIA/TETANUS/ACELLULAR PERTUSSIS AND COMBINATIONS					
<i>Diphtheria, Tetanus, & Pertussis (DTaP)</i>					
90700		Diphtheria, tetanus, and acellular pertussis (whooping cough) (DTaP), intramuscular [<i>Daptacel</i> ; <i>Infanrix</i>]	1	0-6	0.00
<i>Diphtheria & Tetanus (DT)</i>					
90702		Diphtheria and tetanus toxoids, intramuscular [<i>DT</i>]	1	0-7	0.00
<i>Tetanus & Diphtheria (Td)</i>					
90714		Tetanus and diphtheria toxoids, intramuscular [<i>Tenivac</i> , <i>TDVAX</i>]	1	7 - 18	0.00
90714	HA	Tetanus and diphtheria toxoids, intramuscular [<i>Tenivac</i> , <i>TDVAX</i>]	1	19+	32.55
<i>Tetanus, Diphtheria, & Pertussis (Tdap)</i>					
90715		Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular [<i>Boostrix</i> , <i>Adacel</i>]	1	7 - 18	0.00
90715	HA	Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular [<i>Boostrix</i> , <i>Adacel</i>]	1	19+	47.61
<i>Diphtheria & Tetanus Combinations</i>					
90696		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), and polio (DTaP-IPV), intramuscular [<i>Quadracel</i> ; <i>Kinrix</i>]	1	4 - 6	0.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2024

CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
90697		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), polio, Haemophilus influenza type b and hepatitis B (DTaP-IPV-HIB-HEPB), intramuscular [<i>Vaxelis</i>]	1	0-4	0.00
90698		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Haemophilus influenza type B and polio (DTaP-HIB-IPV), intramuscular [<i>Pentacel</i>]	1	0-4	0.00
90723		Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Hepatitis B, and polio (DTaP-HepB-IPV), intramuscular [<i>Pediarix</i>]	1	0-6	0.00
HAEMOPHILUS INFLUENZAE TYPE B (Hib)					
90647		Haemophilus influenzae B (3 dose schedule) injection into muscle [<i>PedvaxHIB</i>]	1	0-5	0.00
90648		Haemophilus influenzae B (4 dose schedule) injection into muscle [<i>ActHIB; Hiberix</i>]	1	0-5	0.00
PNEUMOCOCCAL					
90670		Pneumococcal conjugate 13 valent, intramuscular [<i>Prevnar 13</i>]	1	0-18	0.00
90671		Pneumococcal Congugate Vaccine 15 valent, intramuscular (PCV15) [<i>Vaxneuvance</i>]	1	0-18	0.00
90671	HA	Pneumococcal Congugate Vaccine 15 valent, intramuscular (PCV15) [<i>Vaxneuvance</i>]	1	19+	222.55
90677		Pneumococcal Congugate Vaccine 20 valent, intramuscular (PCV20) [<i>Prevnar 20</i>]	1	0-18	0.00
90677	HA	Pneumococcal Congugate Vaccine 20 valent, intramuscular (PCV20) [<i>Prevnar 20</i>]	1	19+	261.56
90732		Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular [<i>Pneumovax 23</i>]	1	2 - 18	0.00
90732	HA	Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular [<i>Pneumovax 23</i>]	1	19+	117.08
INACTIVATED POLIOVIRUS (IPV)					
90713		Polio vaccine, injection beneath the skin or into muscle [<i>IPOLE</i>]	1	0-18	0.00
INFLUENZA, 2024 - 2025 SEASON					
Influenza (aIV)					
90653		Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use [<i>FLUAD</i>]	1	65+	73.40
Influenza (IIV3)					
90655		Influenza virus vacine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use [<i>Fluzone Preservative Free</i>]*	1	0-2	0.00
90656		Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use [<i>Fluzone Preservative Free</i>]*	1	0-18	0.00
90656	HA	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use [<i>Fluzone Preservative Free</i>]*	1	19+	20.25
90657		Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use [<i>Fluzone</i>]*	1	0-2	0.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2024

CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
90658		Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use[Afluria; FluLaval TIV; Fluzone] *	1	0 - 18	0.00
90658	HA	Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use [Afluria; Fluzone] *	1	19+	21.14
90662		Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use [Fluzone High-Dose]*	1	65+	73.40
Influenza (LAIV3)					
90660		Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use[FluMist]*	1	2-18	0.00
90660	HA	Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use[FluMist]*	1	19+	24.70
Influenza (ccIIV3)					
90661		Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use [Flucelvax]	1	0 - 18	0.00
90661	HA	Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use [Flucelvax]	1	19+	32.45
Influenza (RIV3)					
90673		Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use [Flublok]*	1	18	73.40
90673	HA	Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use [Flublok]*	1	19+	73.40
INFLUENZA, 2023 - 2024 SEASON					
Influenza (IIV4)					
90655		Influenza vaccine for administration into muscle, 0.25ml dosage, preservative free*	1	0-2	0.00
90656		Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free*	1	0 - 18	0.00
90656	HA	Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free*	1	19+	19.76
90657		Influenza vaccine for administration into muscle, 0.25ml dosage*	1	0-2	0.00
90658		Influenza vaccine for administration into muscle, 0.5ml dosage*	1	0 - 18	0.00
90658	HA	Influenza vaccine for administration into muscle, 0.5ml dosage*	1	19+	19.22
90685		Influenza vaccine, intramuscular administration, 0.25ml dosage, quadrivalent, preservation free*	1	0-3	0
90686		Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free*	1	0 - 18	0.00
90686	HA	Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free*	1	19+	19.73
90687		Influenza vaccine intramuscular administration, 0.25ml dosage, quadrivalent*	1	0-3	0.00
90688		Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV*	1	0 - 18	0.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE					
EFFECTIVE: JANUARY 1, 2024					
CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
90688	HA	Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV*	1	19+	18.44
Influenza (LAIV4)					
90672		Influenza vaccine quadrivalent, nasal administration [<i>FluMist Quadrivalent</i>]*	1	2-18	0.00
90672	HA	Influenza vaccine quadrivalent, nasal administration [<i>FluMist Quadrivalent</i>]*	1	19-20	23.75
Influenza (ccIV4)					
90756		Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml*	1	0-18	0.00
90756	HA	Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml*	1	19+	28.52
90674		Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular*	1	0-18	0.00
90674	HA	Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular*	1	19+	30.10
Influenza (RIV4)					
90682	HA	Influenza vaccine derived from DNA for injection into muscle, quadrivalent, preservative and antibiotic free*	1	18	0.00
90682		Influenza vaccine derived from DNA for injection into muscle, quadrivalent, preservative and antibiotic free*	1	19+	73.40
MEASLES, MUMPS, RUBELLA (MMR)					
MMR					
90707		Measles, mumps, and rubella (German measles) injection beneath skin [<i>M-M-R II; Priorix</i>]	1	0-18	0.00
90707	HA	Measles, mumps, and rubella (German measles) injection beneath skin [<i>M-M-R II; Priorix</i>]	1	19+	92.49
MMR/VZV Combination					
90710		Measles, mumps, rubella (German measles), and varicella (chicken pox) injection beneath skin [<i>ProQuad</i>]	1	1 - 12	0.00
VARICELLA (VAR)					
90716		Varicella virus (chicken pox) subcutaneous [<i>Varivax</i>]	1	0-18	0.00
90716	HA	Varicella virus (chicken pox) subcutaneous [<i>Varivax</i>]	1	19+	174.32
HEPATITIS A (HepA)					
90632		Hepatitis A injection into muscle, adult dosage [<i>Vaqta-ADULT; Havrix-ADULT</i>]	1	18	0.00
90632	HA	Hepatitis A injection into muscle, adult dosage [<i>Vaqta-ADULT; Havrix-ADULT</i>]	1	19+	80.92
90633		Hepatitis A (2 dose schedule) injection into muscle, pediatric or adolescent dosage [<i>Vaqta-PEDS; Havrix-PEDS</i>]	1	0-18	0.00
HUMAN PAPILOMAVIRUS (HPV)					
90651		Human papilloma virus Types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (3 dose schedule) injection into muscle [<i>Gardasil 9</i>]	1	9 - 18	0.00
90651	HA	Human papilloma virus Types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (3 dose schedule) injection into muscle [<i>Gardasil 9</i>]	1	19 - 45	287.54
MENINGOCOCCAL					
Meningococcal Conjugate (MenACWY)					

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2024

CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
90619		Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle [MenQuadfi]	1	2-18	0.00
90619	HA	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle [MenQuadfi]	1	19+	166.98
90734		Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use [Menveo]	1	0-18	0.00
90734	HA	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use [Menveo]	1	19+	157.35
Meningococcal Serogroup B (MenB)					
90620		Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C) [Bexsero]	1	10-18	0.00
90620	HA	Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C) [Bexsero]	1	19+	223.75
90621		Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp) [Trumenba]	1	10-18	0.00
90621	HA	Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp) [Trumenba]	1	19+	190.26
Meningococcal and Haemophilus Influenzae (Hib-MenCY)					
90644		Meningococcal and Haemophilus influenzae B (4 dose schedule) injection into muscle, children 6 weeks-18 months of age (Hib-MenCY)	1	0-2	0.00
ZOSTER RECOMBINANT (RZV)					
90750		Zoster Vaccine (HZC) recombinant, intramuscular [SHINGRIX]	1	18+	197.90
RABIES					
90375		Rabies immune globulin for injection beneath skin and/or into muscle [HyperRAB]	9		285.65
90376		Rabies immune globulin for injection beneath skin and/or into muscle, heat treated [Imogam Rabies - HT]	9		479.72
90675		Rabies vaccine, intramuscular [Imovax Rabies; RabAvert]	1		322.77
RESPIRATORY SYNCYTIAL VIRUS					
90380		Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 0.5ml dosage for IM use (BEYFORTUS)^	1	0-1	0.00
90381		Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^	1	0-1	0.00
90381		Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^	2	1-2	0.00
96380		Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular, with counseling^	1	0-2	10.00
96381		Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular^	1	0-2	10.00
90678		Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use [ABRYSVO]	1	10-18 (PREGNANCY ONLY)	295.00

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2024

CPT Code	Modifier	Description	Units	Age (Years)	MaxFee
90678	HA	Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use [ABRYSVO]	1	19-59 (PREGNANCY ONLY)	295.00
90678	HA	Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use [ABRYSVO]	1	60+	295.00
90679		Respiratory Syncytial Virus vaccine, for IM use [AREXVY]	1	60+	280.00
90683		Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use [mRESVIA]	1	60+	290.00
COVID-19 VACCINE & ADMINISTRATION CODES					
90480		Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (all manufacturers)*	1	ANY	40.00
91304		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 0.5mL dosage, for intramuscular use (Novavax)	1	12-18	0.00
91304	HA	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 0.5mL dosage, for intramuscular use (Novavax)	1	19+	148.20
91318		Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	6MO-4YRS	0.00
91319		Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	5-11YRS	0.00
91320		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	12-18	0.00
91320	HA	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)*	1	19+	131.10
91321		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.25 mL dosage, for intramuscular use (Moderna)*	1	6MO-11YRS	0.00
91322		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)*	1	12-18	0.00
91322	HA	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)*	1	19+	145.92